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A b s t r A c t
Renal artery stenosis (RAS) is a relatively common condition in the elderly, especially 
in the setting of concomitant vascular disease in other anatomical sites and is most 
often of atheromatous origin. Rarely is it encountered in young women as a result of 
fibromuscular dysplasia. RAS is considered responsible for refractory or accelerated 
hypertension, progressive loss of renal function and deterioration of patients’ cardio-
vascular status, with episodes of angina or pulmonary oedema disproportional to the 
extent of coronary artery disease and left ventricle functional capacity, dominating 
the clinical presentation. This article summarizes the pathophysio logical implications 
and diagnostic methods and attempts a review of the current literature on indications 
and efficacy of the available therapeutic options for RAS, focusing on intervention-
al treatment. Renal artery stenosis (RAS) is most commonly due to atherosclerosis 
(≈0%) or fibromuscular dysplasia (10%) and rarely to extrinsic compression, neuro-
fibromatosis type I or Williams syndrome. Fibromuscular dysplasia predominates in 
young women (30-50 years old), is a nonatherosclerotic, noninflammatory vascular 
disease that causes stenosis in medium and small arteries, most commonly involving 
the distal 2/3 of the renal artery and carotid arteries. Atherosclerotic renal artery 
stenosis is usually encountered in males over 55 years old and often occurs at the os-
tium or the proximal 2 cm of the artery. [1,2] Refractory hypertension, progressive re-
nal function deterioration and recurrent episodes of decompensated heart failure or 
flash pulmonary oedema are the most common clinical manifestations of the disease 
Both conservative and interventional treatment have been proposed and applied with 
comparable efficacy, as far as atherosclerotic disease is concerned and thus certain 
controversies have arisen regarding the treatment of choice.[3]
E P I D E m I O L O G Y
The true epidemiology of renal artery disease is less well-known, [4] because 
the majority of such data are derived from studies of patients undergoing other pro-
cedures, mainly cardiac catheterization. The prevalence of RAS in the elderly has 
been reported to be 6.8%. In individuals with coronary heart disease, RAS coexists 
in 15-23% and in cases of aortoiliac or lower extremity vascular disease it is found in 
28-38% and 45-5% respectively. [4-7] In the most extensive study so far [4,8] 11% of 
patients undergoing cardiac catheterization had greater than 50% unilateral narrowing 
of the renal artery, 2.4% had bilateral 50-75% and 16% had >75% bilateral stenoses. 
In this study the severity of the disease was predicted by old age, gender, peripheral 
vascular disease, congestive heart failure, renal insufficiency, smoking and the degree 
of coronary artery involvement. 
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c L I N I c A L  I m P L I c A t I O N s 
Renal artery disease has 2 cardinal pathophysiological 
consequences. A) It leads to renin-angiotensin-aldosterone 
system activation [in unilateral (Goldblatt) stenosis] and B) 
reduces glomerular filtration and salt and water extraction 
(bilateral artery stenosis or stenosis of the renal artery of a 
solitary kidney). Most patients remain clinically asymptomatic 
due to the large kidney functional reserve. Incidental RAS is 
usually identified during imaging of other vessels i.e. while 
performing coronary or peripheral vascular angiography. 
Hypertension usually with abrupt onset in persons <30 years 
of age could be a manifestation of fibromuscular dysplasia. If 
the diagnosis is first made in the age over 50, atherosclerotic 
RAS should be considered. Accelerated, malignant or resis-
tant hypertension should point the diagnostic view towards 
RAS [1,4]. Patients developing progressive renal failure which 
may be ischemic or drug induced (administration of ACEI or 
ARBs), as well as unexplained hypokalemia (secondary aldo-
steronism), ought to be examined for renal artery disease. The 
presence of flank bruit or atherosclerotic disease elsewhere 
in the body may be supportive findings. Kidney size is also an 
important parameter. It has been reported that 71% of patients 
with an atrophic kidney (length <7cm), have severe stenosis 
of the renal artery ipsilateral to the small kidney [1]. Three 
studies have shown that, if a discrepancy in size between the 
2 kidneys of greater than 1.5 cm exists, there is a 60% chance 
that the contralateral renal artery (normal sized kidney) is 
severely stenotic [1,]. Finally, recurrent episodes of congestive 
heart failure and flash pulmonary oedema, in the absence of 
significant myocardial ischemia or impaired left ventricular 
systolic function can result from bilateral RAS or unilateral to 
a single functioning kidney [1,,10]. Tables 1 and 2 summarize 
the clinical manifestations of the disease.
D I A G N O s I s
Both imaging and functional assessment has been used 
in RAS evaluation. In cases of high clinical suspicion an 
imaging modality should be employed. Captopril renography, 
duplex ultrasonography of the renal arteries, spiral computed 
tomography with angiography (CTA), gadolinium magnetic 
resonance angiography (MRA) and contrast arteriography 
have been used. (Table3). 
Captopril renography: Captopril (or other ACEIs) mag-
nifies the functional difference between kidneys reducing 
glomerular filtration rate by 30% in the stenotic kidney. This 
leads to accumulation of radionuclide in the affected kidney. 
The test provides an indirect assessment of renal blood supply 
and presents a sensitivity of 85-0% and specificity of 3%, 
providing that one of the kidneys is normal. The presence 
of renal insufficiency (creatinine ≥2mg/dl) or bilateral RAS 
severely influences the tests accuracy raising the likelihood 
of false positive scans. [1,10-12]
Doppler ultrasound of the renal arteries allows reliable 
serial estimation of flow velocities. A rise in velocity to more 
than 200 cm/sec or to a value higher than the aortic velocities 
with renal-aortic ratio 3.5 is considered predictive of more 
than 60% luminal narrowing [1,10,13,14]. Assesment of post-
stenotic blood flow and vascular resistance within the kidney 
tAbLE1. Clinical Manifestations of Renal Artery Steno-
sis
Poorly controlled hypertension refractory to medical therapy•
Worsening renal function•
Accelerated cardiovascular disease•
Flash pulmonary edema•
tAbLE 2. Clinical Clues to the Diagnosis of Atherosclerotic 
Renal Artery Stenosis
• Onset of hypertension after the age of 55
• Exacerbation of previously well-controlled hypertension
• Malignant hypertension
• Resistant hypertension
• Epigastric bruit (systolic/diastolic)
• Unexplained azotemia
• Azotemia while receiving angiotensin-converting enzyme 
inhibitors or angiotensin receptor blocking agents
• Atrophic kidney or discrepancy in size between the two kidneys
• Recurrent congestive heart failure or “flash” pulmonary 
edema
• Atherosclerosis elsewhere
tAbLE 3. Diagnostic Modalities Used to Diagnose Renal 
Artery Stenosis
test sensitivity (%) specificity (%)
Captopril scan 85–0 0
Renal duplex 8 
CT 8–100 82–100
MRI/MRA 1–100 71–100
Angiography 8 100
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(resistive index) provides a guide to the potential salvageability 
of the kidney and the likelihood of BP response post inter-
ventionally. The method exhibits an 84-8% sensitivity and 
62-% specificity, is safe and cost-effective. However, it does 
not provide us with any functional assessment of the kidney, 
the method is technically demanding and time consuming, 
some individuals are not suitable for the study and accessory 
renal arteries cannot be reliably identified.
CT angiography (CTA) has an 8-100% sensitivity and 82-
100% specificity [10,15,16]. Because it requires large amounts 
of nephrotoxic contrast medium, its use in azotemic patients 
is limited. Gadolinium contrast MRA provides visualization 
of the main renal arteries with high sensitivity (1-100%) and 
specificity (76-4%), and offers the most complete non-inva-
sive imaging of the renal vasculature with a nonnephrotoxic 
agent.. It is limited by cost, availability and by the fact that it 
may miss distal vascular lesions or accessory vessels. 
Contrast arteriography still remains the “gold standard” for 
diagnosing RAS, performed at the time of planned endovas-
cular intervention (balloon angioplasty or stent deployment). 
The hazards include atheroembolic disease and contrast ne-
phrotoxicity especially in older or diabetic patients. The use 
of non-toxic agents such as gadolinium or carbon dioxide may 
be beneficial in cases of renal insufficiency. [10,12]
Functional tests are used to establish whether a) hemo-
dynamically significant lesions impair blood flow or activate 
renin release and b) correction of the vascular lesion can 
produce improvement in blood flow or renal function. They in-
clude plasma renin activity (PRA), captopril stimulated PRA, 
renal vein renin activity, intravenous pyelography, iodine-125 
DTPA scan (glomerular filtration assessment), captopril re-
nography with Tc-mercaptotriglycylglycine, radionuclide scan 
with Tc m (renal blood flow assessment). These tests require 
comparison of a stenotic kidney with a presumed normal 
contralateral kidney, which is often actually abnormal. [10,17] 
Furthermore, indices of renal function (creatinine >3mg/dl) 
and proteinuria are important of predicting recovery of kidney 
function after surgical or endovascular repair. [12]
t r E A t m E N t
Treatment decisions for the management of RAS should 
consider relative benefits and risks involved and must take 
into account the likelihood of blood pressure reduction and 
renal parenchyma preservation. In general, medical therapy is 
considered in cases of underlying advanced nephropathy with 
unilateral RAS and creatinine >2.5 mg/dl, renal length <7 cm, 
proteinuria >1 gr/day, severe diffuse intrarenal disease and 
target kidney resistive index >80. Medical therapy includes 
antihypertensive, cholesterol-lowering and antiplatelet drugs. 
ACEIs, ARBs, calcium channel blockers and β-blockers are 
commonly used with proven efficacy and safety. However a 
potential consequence of conservative therapy is disease pro-
gression as reported by small series [18-20] potentially leading 
to renal artery occlusion, which makes even the endovascular 
therapy extremely difficult. Another consideration would be 
the possibility of progressively worsening renal function, lead-
ing to end stage renal disease. Interestingly, a retrospective 
cohort evaluation suggests that serum creatinine levels remain 
stable for numerous years,[18,21] but the small numbers of 
patients observed makes it hard to base real clinical manage-
ment decisions on such reports. 
Revascularization is favoured in patients with bilateral 
RAS and creatinine >1.5 mg/dl, unilateral RAS and frac-
tional glomerular filtration rate <40%, ACEI induced renal 
failure, hypertensive crisis and non ischaemic pulmonary 
edema. (Table 3). [10] Revascularization can be attempted by 
intraluminal intervention or surgery. The surgical techniques 
include aortorenal, hepatorenal or splenorenal by pass [22,23]. 
Nowadays, medical and endovascular methods have become 
more established, but surgery still retains a role. Current 
indications for surgical revascularisation include: occluded 
renal artery with preserved renal parenchyma, RAS with 
Takayasu’s arteritis, RAS with multiple small renal arteries 
or early primary branching of the main renal artery, branch 
disease from FMD that cannot be treated adequately with 
balloon angioplasty, especially in patients exhibiting complex 
disease that extends into the segmental arteries and those 
having macroaneurysms, recurrent stenosis after stenting 
or simultaneous aortic surgery (abdominal aortic aneurysm 
repair or symptomatic aortoiliac disease). Even in this last 
circumstance, it may be advisable to stent the renal artery first 
and then proceed with aortic reconstruction. The mortality 
rate of aortic replacement and renal artery revascularisation 
is higher than for either procedure alone. [22]
Current recommendations (ACC/AHA) for renal artery 
revascularization include: 
Asymptomatic RAS in case of bilateral or solitary viable 
kidney with a hemodynamically significant RAS. (class 
IIb LOE C).
Accelerated hypertension, resistant hypertension, ma-
lignant hypertension, hypertension with an unexplained 
unilateral small kidney, and hypertension with intolerance 
to medication in patients with hemodynamically significant 
-
-
tAbLE 4. Indications for Renal Artery Revascularization
 ≥50% stenosis•
 Translesional systolic pressure gradient ≥15 mm Hg•
 Difficult-to-control hypertension•
 Worsening renal function •
 Nonischemic pulmonary edema•
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RAS (class IIa LOE B).
Progressive chronic kidney disease with bilateral RAS or a 
RAS to a solitary functioning kidney (class IIa LOE B).
RAS and chronic renal insufficiency with unilateral RAS 
(class IIb LOE C).
hemodynamically significant RAS and recurrent, unex-
plained congestive heart failure or sudden, unexplained 
pulmonary edema (class I LOE B).
hemodynamically significant RAS and unstable angina 
(class IIa LOE B). [24]
Single balloon angioplasty is the treatment of choice in 
fibromuscular dysplasia. However in atherosclerotic lesions, 
stent placement is indicated in order to minimize the risk of 
procedure failure and the restenosis rate. Van de Ven et. al. 
performed a trial in 1 comparing 42 patients undergoing 
renal artery angioplasty with 45 patients receiving angioplasty 
and stenting. They found that success as well as patency rates 
were significantly higher in the second group although the dif-
ferencies in renal function or blood pressure were stasistically 
non significant. Similar results were reported by Rundback 
et al. [25,26]
t E c H N I q U E  O f  A N G I O P L A s t Y  
( P t r A )  &  s t E N t I N G
Until the beginning of the 10s, balloon angioplasty 
was the only method of percutaneous treatment of renal 
artery stenosis with satisfying acute and long-term results for 
angioplasty of stenoses caused by FMD and atherosclerotic 
stenosis of the renal artery trunk. [27-2] However, balloon 
angioplasty of ostial atherosclerotic lesions was limited by a 
low acute technical success rate (50–62%) and a high rest-
enosis rate of up to 47% over the long term because of the 
potential for dissection and elastic recoil or rigidity of the 
lesion. [30] The introduction of stenting has revolutionized 
percutaneous renal revascularization. Following promising 
single center reports [31,32], two randomized studies proved 
the superiority of stenting over conventional balloon angi-
oplasty [25,33] in the treatment of atherosclerotic ostial renal 
artery stenosis, the most common manifestation of renal artery 
stenosis. Nowadays using premounted low profile stent devices 
(“nested ring design”), atherosclerotic renal artery stenosis can 
be successfully treated in about 100% of cases with restenosis 
rates ranging from 0% to 23% depending on the diameter of 
the renal artery. [2,34]
Currently, the guiding catheter technique is the proce-
dure of choice with the lowest intervention and radiation 
time. Selective catheterization of the renal artery is usually 
performed through the guiding catheter using a steerable 
0.014 or 0.018 inch stiff guidewire with a flexible tip. Except 
in case of subtotal occlusion, direct stenting is feasible in 
almost all cases of ostial renal artery stenosis using the new 
-
-
-
-
flexible low profile stent devices. In rare cases of unfavorable 
anatomy, the brachial approach is a reliable alternative. An 
alternative technique is the use of a guiding sheath or long 
preshaped sheath: this device (e.g., Vista Britetip IG, Cordis 
Corp., Miami, FL, USA) combines the traditional sheath with 
a guiding catheter. Adverse events reported in angioplasty 
studies included death by 30 days in up to 3% of patients, 
transient deterioration of kidney function in 1% to 13%, renal 
artery or parenchymal injury in up to 5%, and periprocedural 
cardiovascular events in up to 3%. Other adverse events that 
have been reported are hemorrhage, hematomas, and renal 
artery occlusion. Seventeen studies of angioplasty with stent 
placement showed restenosis rates that ranged from 10% to 
21% during follow-up of 3 to 40 months. [35-37]
The main causes of renal function deterioration after the 
procedure are embolism and contrast-induced nephropathy. To 
avoid renal embolism prior to selective renal angiography, the 
guiding catheter should be cleaned from debris by aspiration 
of blood through the guiding catheter (“proximal protection”). 
This technique cleans the tip of the guiding catheter from 
debris collected during the engagement of the renal artery 
and therefore reduces the risk of renal embolization. The use 
of distal protection devices is limited by the anatomy of the 
renal artery [2], but recently there have been reports about 
the use of such devices in renal intervention. [38] To avoid 
contrast-induced nephropathy, nowadays carbon dioxide or 
gadodiamide can be used as alternative contrast agents if 
digital subtraction technique is available. [3,40] Furthermore, 
the development of less nephrotoxic contrast agents such as 
iodixanol (an iso-osmolar, nonionic-iodinated contrast agent), 
nephroprotective agents, and pre- and post-interventional 
hydration of the patient have also led to a reduction of the 
frequency of contrast nephropathy. [2] 
Another future development is the use of drug eluting 
stents for renal application. The GREAT trial found that the 
blood pressure and angiographic outcome at 6 months did not 
show a significant difference between bare metal and sirolimus 
eluting stents, but the small number of patients examined may 
had influenced the results [41]. Thus, future studies with a 
larger patient population and longer angiographic follow-up 
are warranted to determine if there is a significant benefit 
of drug-eluting stents in treating ostial renal artery stenosis. 
However, an increased restenosis rate is only a matter of con-
cern in small renal arteries with a diameter of 5 mm or less, 
[42] and drug-eluting stents may be indicated only for these 
vessels. Lower rates of mortality, stroke, myocardial infarction 
and azotemia, and better blood pressure control have been 
reported in patients receiving renal artery stenting compared 
to those treated only medically (87% 5-year survival vs 67%). 
[30,43] However, two recent studies (DRASTIC, Scottish…) 
failed to prove the superiority of interventional treatment. The 
Scottish study was unable to demonstrate any benefit in respect 
of renal function or event-free survival. The DRASTIC study 
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concluded that angioplasty has little advantage over medical 
therapy in individuals with hypertension and RAS, but the 
crossover of patients between the medical and angioplasty 
group was numerous so that the results are considered virtu-
ally uninterpretable. [1,20,44]
So far the available evidence are neither adequate nor suf-
ficiently applicable to current practice to clearly support one 
treatment approach over another for the general population 
with RAS. Blood pressure (classified as cured, improved or 
unchanged) can be decreased adequately with combination an-
tihypertensive medication but intervention may lead to better 
control, particularly in cases of bilateral vascular disease. Both 
medical and interventional approaches lower it, but almost 
all angioplasty studies report that some persons (18%) were 
cured of hypertension [2,35]. However randomized studies re-
garding blood pressure control are seriously flawed. Although 
most practitioners consider significant a stenosis over 70%, 
the studies encorporated patients with stenosis >50%, which 
notably is consistent with the last guidelines published by ACC. 
Crossover between persons randomized in the angioplasty or 
conservative branch [3,1] in two studies, makes their results 
rather confusing, neither supporting nor refuting the potential 
benefits of revascularization.
Most studies suggest no large differences in mortality 
rates, cardiovascular events or change in kidney function 
between patients treated only medically and those receiving 
angioplasty. Within the published studies of angioplasty, 8-51% 
of patients improved their kidney function while approximately 
31% worsened it. [35]
The existing trials so far have also failed to demonstrate 
hard evidence on kidney function improvement with either 
conventional or invasive therapy [3]. It is a fact that there is 
poor correlation between the degree of anatomic stenosis 
and glomerular filtration rate. Nuclear studies have shown 
that GFR in the non stenotic kidney is often the same or even 
lower than that in the kidney distal to a stenosis [3,33]. This 
phenomenon probably relates to the presence of ischaemic 
damage in the post stenotic kidney and hypertensive injury 
to the non stenotic one, which also explains why filtration rate 
often fails to improve significantly after revascularization. 
Observational studies report that kidney function may stabilize 
or get better in some individuals. On the other hand, inter-
ventional therapy may itself cause declines in renal function 
either from contrast nephropathy or atheroembolic disease. 
(Table 5). In the largest prospective randomized trial, there 
was no difference in kidney function in the two groups of 
patients one year later. [3]
Another clinical condition associated with RAS as already 
mentioned, is flash pulmonary edema. There are studies dem-
onstrating decline of hospitalization for such reasons after 
renal artery stenting and NYHA class improvement, but the 
concomitant increase in the use of ACEI observed during the 
study may have contributed to the improved outcome. [3,36] 
Scottish and Newcastle Renal Artery Stenosis Collaborative 
Group found no differencies in event rates for congestive heart 
failure, stroke or myocardial infarction across 54 months of 
follow –up between the two groups. [20,35] Studies comment-
ing on survival, were generally too small to detect anything but 
large differences in mortality rates, and no large differences 
in mortality rates were found. Mortality rates greater than 
40% within 6 years occurred mostly in studies of patients with 
high-grade stenosis (>75%) or bilateral disease [35]. Ischemic 
nephropathy is an important cause of end stage disease and 
among patients who are receiving dialysis, those with reno-
vascular disease have the lowest survival rate with a median 
survival of 25–34 months and a 5-year mortality rate of more 
than 80%. Left ventricular cardiac dysfunction, age, and a 
baseline creatinine level of more than 2.5 mg/dL are reported 
to be independent predictors of mortality. [2]  The cause of 
death was congestive heart failure or myocardial infarction 
(73%), stroke (13.5%), and malignant disease (13.5%). [12]
In general the existing data cannot establish the neces-
sity for angioplasty in patients fullfilling the so far accepted 
indications without endorsement of additional criteria. Obvi-
ously some of them benefit from the interventional procedure 
while others do not or even experience deterioration of their 
clinical or laboratory status. The studies of diagnostic tests 
were inadequate to determine whether any such test may pre-
dict long-term outcome or guide best treatment approaches. 
Weak evidence suggests that patients with bilateral disease 
may preferentially benefit from angioplasty over medical 
tAbLE 5. Complication of PTA (±stenting) of renal 
arteries
Local renal (3–83%) 
1. Contrast-induced acute renal failure (ARF) (mild or severe) 
2. Atheroembolic renal failure (0.5%) 
3. Rupture of the renal artery 
4. Dissection of the renal artery 
5. Thrombotic occlusion of the renal artery (2%)
6. Occlusion of a branch renal artery (0.5%)
7. Balloon rupture or malfunction (may lead to inability to remove 
the balloon)
8. Renal artery spasm
Puncture site  
1. Hematoma, hemorrhage or vessel tear (3–48%)
2. Brachial plexus compression (axillary approach)
3. Pseudoaneurysm (0.5%)
4. AV fistula (0.1%)
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treatment. Clinical symptoms and signs or laboratory values 
can also serve as predictive factors. Impaired kidney function 
predicts a higher mortality rate, poorer clinical outcomes 
including cardiovascular events and worse blood pressure 
control. On the other hand prior cardiovascular disease cor-
relates with increased mortality rates and worsening renal 
function. [1,20,35-37,45-47]
Among the published studies four diagnostic tests have 
been evaluated to determine their value in predicting treat-
ment outcomes in RAS. The DRASTIC study found that 
neither captopril test nor renography can predict kidney 
function or blood pressure control after treatment. [35,45] 
Two cohort studies evaluated the role of baseline resistive 
index of >80%. In the first one, people with elevated RI were 
most likely to benefit after angioplasty and stenting in terms 
of blood pressure and renal function, while in the second the 
same individuals were more likely to have worsening renal 
function and poorer blood pressure control after angioplasty 
with or without stenting. [48,4] Another study reported that 
non spiral flow on MRA predicts significantly worse kidney 
function outcomes. [50]
What becomes evident from this discussion is that un-
til now there are no undoubted evidence to either prove 
interventional approach’s superiority compared to medical 
therapy or determine the subgroup of patients which is likely 
to benefit from one or the other treatment option. More large 
randomized prospective controlled trials are needed in order 
to provide hard evidence on these controversial issues. Three 
ongoing studies are expected to enlighten this field. The 
CORAL and the STAR studies are comparing the effects of 
angioplasty with stent placement and optimal medical therapy, 
to medical therapy alone on a composite end point of adverse 
cardiovascular and renal events. [51,52] The 3R study aims at 
comparing the effect of endovascular revascularization versus 
medical therapy in 300 patients. [53] Their results will probably 
address many of the deficiencies in current evidence about 
revascularization and medical treatment comparison and may 
provide useful information on the value of different diagnostic 
tests on determining which therapeutic method is best for 
individual patients. However, more studies are necessary to 
avoid a spontaneous generalization of those trial’s results, 
which may lead to inappropriate treatment, misallocated 
resources and worse outcomes in case that these finding be 
applied to patients with different characteristics from those 
incorporated in the studies. 
c O N c L U s I O N s
RAS is a rather common condition that threatens the 
quality of life as well as the survival of patients. The thera-
pies endorsed so far are of no undoubted effectiveness and 
interventional approach may hold advantage for certain suit-
able individuals although the existing evidence is not enough 
to establish this fact. Renal artery stenting is a particularly 
promising revascularization technique but further studies are 
needed to prove its superiority over medical treatment alone. 
The aim of the clinician must therefore be the primary and 
secondary prevention of renal atherosclerosis, the achievement 
of an earlier diagnosis and the selection of the appropriate 
treatment (conservative vs interventional) considering the 
overall prognosis of the patient.
r E f E r E N c E s
 1.  Olin JW. Renal artery disease: diagnosis and management. Mt 
Sinai J Med 2004;71:73-85. 
 2.  Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 
2001; 344: 431-442. 
 3.  Dworkin LD, Jamerson KA. Case against angioplasty and 
stenting of atherosclerotic renal artery stenosis. Circulation 
2007;115: 271-276. 
 4.  Zoccali C, Mallamaci F, Finocchiaro P. Atherosclerotic renal 
artery stenosis: epidemiology, cardiovascular outcomes, and 
clinical prediction rules. J Am Soc Nephrol 2002; 13 Suppl 
3:17-183.
 5.  Olin JW, Melia M, Young JR, Graor RA, Risius B. Prevalence 
of atherosclerotic renal artery stenosis in patients with athero-
sclerosis elsewhere. Am J Med 10; 88: 46–51. 
 6.  Valentine RJ, Myers SI, Miller GL, Lopez MA, Clagett GP. 
Detection of unsuspected renal artery stenosis in patients with 
abdominal aortic aneurysms: Refined indications for preopera-
tive aortography. Ann Vasc Surg 13; 7: 220-224.
 7.  Wilms G, Marchal G, Peene P, Baert AL. The angiographic 
incidence of renal artery stenosis in the arteriosclerotic popula-
tion. Eur J Radiol 10; 10: 15–17.
 8.  Harding MB, Smith LR, Himmelstein SI, et al. Renal artery 
stenosis: Prevalence and associated risk factors in patients un-
dergoing routine cardiac catherization. J Am Soc Nephrol 12; 
2: 1608–1616. 
 .  Olin JW, Begelman SM. Renal artery disease. In: Topol E (ed). 
Textbook of cardiovascular medicine, 2nd ed Lippincott Raven, 
Philadelphia, 2002, pp. 213 – 215.
 10.  Bokhari SW, Faxon DP. Current advances in the diagnosis and 
treatment of renal artery stenosis. Rev Cardiovasc Med 2004; 5: 
204-215.
 11.  Nally JV, Clarke HS Jr, Grecos GP, et al. Effect of captopril on 
mTc-diethylenetriaminepentaacetic acid renograms in two 
kidney, one clip hypertension. Hypertension 186; 8: 685 – 63.
 12.  Textor SC. Evaluation of renovascular disease. In: Greenberg 
A (ed). Primer on kidney diseases, National kidney foundation, 
New York, NY, 18, pp. 366-36.
 13.  Olin JW, Piedmonte MR, Young JR, et al. The utility of duplex 
ultrasound scanning of the renal arteries for diagnosing signifi-
cant renal artery stenosis. Ann Intern Med 15; 122:833–838.
 14.  Prince MR, Schoenberg SO, Ward JS, et al. Hemodynami-
cally significant atherosclerotic renal artery stenosis: MR angi-
ographic features. Radiology 17; 205:128–136.
RENAL ARTERY STENTING
227
 15. Rubin GD, Dake MD, Napel S, et al. Spiral CT of renal ar-
tery stenosis: comparison of threedimensional rendering tech-
niques. Radiology 14; 10:181–18.
 16.  Willmann JK, Wildermuth S, Pfammatter T, et al. Aortoiliac 
and renal arteries: prospective intraindividual comparison of 
contrastenhanced three-dimensional MR angiography and 
multi-detector row CT angiography. Radiology 2003; 226:78–
811.
 17.  Mann SJ. Captopril renal scan for detecting renal artery steno-
sis. Arch Intern Med 2003; 163:630–631.
 18.  Covit AB. Medical treatment of renal artery stenosis: is it effec-
tive and appropriate? J Hypertens Suppl 2005; 23: 15-22.
 1.  van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of 
balloon angioplasty on hypertension in atherosclerotic renal-
artery stenosis. Dutch Renal Artery Stenosis Intervention Co-
operative Study Group. N Engl J Med 2000; 342: 1007–1014.
 20.  Webster J, Marshall F, Abdalla M, et al. Randomised compari-
son of percutaneous angioplasty vs. continued medical therapy 
for hypertensive patients with atheromatous renal artery steno-
sis. Scottish and Newcastle Renal Artery Stenosis Collabora-
tive Group. J Hum Hypertens 18; 12: 32–335.
 21.  Leertouwer TC, Pattynama PMT, van den Berg-Huysmans A. 
Incidental renal artery stenosis in peripheral vascular disease: 
a case for treatment? Kidney Int 2001; 5:1480–1483.
 22. Mwipatayi BP, Beningfield SJ, White LE, Irish A, Abbas M, 
Sieunarine K. A review of the current treatment of renal artery 
stenosis. Eur J Vasc Endovasc Surg 2005;2 : 47-88. 
 23. Cambria RP, Brewster D, L’Itlaien B, et al. The durability of 
different reconstructive techniques for atherosclerotic renal 
artery disease. J Vasc Surg 14; 20: 76–85.
 24.  Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 
guidelines for the management of patients with peripheral arte-
rial disease (lower extremity, renal, mesenteric, and abdominal 
aortic): executive summary. J Am Coll Cardiol 2006; 47:123-
312.
 25.  Van de Ven PJG, Kaatee R, et al. Arterial stenting and bal-
loon angioplasty in ostial atherosclerotic renovascular disease: 
a randomized trial. Lancet 1; 353: 282–286.
 26.  Rundback J, Manoni T, Rozenblit G, et al. Balloon angioplasty 
or stent placement in patients with azotemic renovascular dis-
ease. Heart Dis 1; 1:121–125.
 27.  Martin LG, Cork RD, Kaufman SL. Long-term results of an-
gioplasty in 110 patients with renal artery stenosis. J Vasc Interv 
Radiol 12; 3: 61–626.
 28.  Klinge J, Mali WP, Puijlaert CB, et al. Percutaneous translumi-
nal renal angioplasty: Initial and long-term results. Radiology 
18; 171: 501–506.
 2. Zeller T. Renal artery stenosis: epidemiology, clinical mani-
festation, and percutaneous endovascular therapy. J Interven 
Cardiol 2005; 18: 47–506. 
 30.  Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal-
artery stenoses with vascular endoprostheses after unsuccess-
ful balloon angioplasty. N Engl J Med 17; 336: 45–465. 
 31.  Taylor A, Sheppard D, Macleod MJ, et al. Renal artery stent 
placement in renal artery stenosis: Technical and early clinical 
results. Clin Radiol 17; 52: 451–457.
 32.  van de Ven PJ, Beutler JJ, Kaatee R, et al. Transluminal vascu-
lar stent for ostial atherosclerotic renal artery stenosis. Lancet 
15; 346: 672–674.
 33.  Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure 
outcome of angioplasty in atherosclerotic renal artery steno-
sis: a randomized trial. Essai Multicentrique Medicaments vs. 
Angioplastie (EMMA) Study Group. Hypertension 18; 31: 
823–82. 
 34. Zeller T, Frank U, Mόller C, et al. Technological advances in the 
design of catheters and devices used in renal artery interven-
tions: Impact on complications. J Endovasc Ther 2003;10:1006–
1014.
 35.  Balk E, Raman G, Chung M, et al. Effectiveness of manage-
ment strategies for renal artery stenosis: a systematic review. 
Ann Intern Med 2006 1; 145: 01-12. 
 36.  Gray BH, Olin JW, Childs MB, et al. Clinical benefit of renal 
artery angioplasty with stenting for the control of recurrent and 
refractory congestive heart failure. Vasc Med 2002; 7: 275–27.
 37.  Kennedy DJ, Colyer WR, Brewster PS, et al. Renal insuffi-
ciency as a predictor of adverse events and mortality after renal 
artery stent placement. Am J Kidney Dis 2003; 42:26-35. 
 38.  Henry M, Klonaris C, Henry I, et al. Protected renal stenting 
with the PercuSurge GuardWire device: A pilot study. J Endo-
vasc Ther 2001; 8: 227–237.
 3.  Zeller T, Mόller C, Frank U, et al. Gadodiamide as an alter-
native contrast agent during angioplasty in patients with con-
traindications to iodinated media. J Endovasc Ther 2002; : 
625-632.
 40.  Strunk H, Schild H, Mortasawi MA. Arterial interventional 
measures using carbon dioxide (CO2) as a contrast medium. 
Rofo Fortschr Geb Rontgenstr Neue Bildgeb Verfahr 12; 
157:5–600.
 41. Zöhringer M, Sapoval M, Pattynama PM, et al. Sirolimus-elut-
ing versus bare-metal low-profile stent for renal artery treat-
ment (GREAT Trial): angiographic follow-up after 6 months 
and clinical outcome up to 2 years. J Endovasc Ther 2007;14: 
460-468.
 42.  Zeller T, Mόller C, Frank U, et al. Gold coating and restenosis 
after primary stenting of ostial renal artery stenosis. Catheter 
Cardiovasc Interv 2003; 60: 1–6.
 43.  Cooper CJ, Murphy TP. Is renal artery stenting the correct 
treatment of renal artery stenosis? The case for renal artery 
stenting for treatment of renal artery stenosis. Circulation 2007; 
115: 263-26.
 44.  Levin A, Linas S, Luft FC, Chapman AB, Textor S; ASN HTN 
Advisory Group. Controversies in Renal Artery Stenosis: A Re-
view by the American Society of Nephrology Advisory Group 
on Hypertension. Am J Nephrol 2007; 27:212–220.
 45.  Krijnen P, van Jaarsveld BC, Deinum J, et al. Which patients 
with hypertension and atherosclerotic renal artery stenosis 
benefit from immediate intervention? J Hum Hypertens 2004; 
18:1-6.
 46.  Johansson M, Herlitz H, Jensen G, et al. Increased cardiovas-
cular mortality in hypertensive patients with renal artery ste-
228
HOSPITAL CHRONICLES, SUPPLEMENT 2008
nosis. Relation to sympathetic activation, renal function and 
treatment regimens. J Hypertens 1; 17: 1743-1750.
 47.  Uzzo RG, Novick AC, Goormastic M, et al. Medical versus 
surgical management of atherosclerotic renal artery stenosis. 
Transplant Proc 2002; 34: 723-725.
 48.  Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultra-
sonography to predict the outcome of therapy for renal artery 
stenosis. N Engl J Med 2001; 344:410-417.
 4.  Zeller T, Frank U, Mu¨ller C, et al. Stent supported angioplasty 
of severe atherosclerotic renal artery stenosis preserves renal 
function and improves blood pressure control: long-term re-
sults from a prospective registry of 456 lesions. J Endovasc Ther 
2004; 11: 5-106.
 50.  Houston JG, Gandy SJ, Milne W, et al. Spiral laminar flow 
in the abdominal aorta: a predictor of renal impairment de-
terioration in patients with renal artery stenosis? Nephrol Dial 
Transplant 2004; 1: 1786-171.
 51.  Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascu-
larization for the prevention of cardiovascular and renal events 
among patients with renal artery stenosis and systolic hyper-
tension: rationale and design of the CORAL trial. Am Heart J 
2006; 152: 5-66. 
 52.  Bax L, Mali WP, Buskens E, et al. The benefit of stent place-
ment and blood pressure and lipid lowering for the prevention 
of progression of renal dysfunction caused by atherosclerotic 
ostial stenosis of the renal artery. STAR-study: rationale and 
study design. J Nephrol 2003; 16: 807–812.
 53.  Zuccala A, Zucchelli P, Campieri C, et al. 3 R study: renal 
ischemia: revascularisation or medical treatment. J Nephrol 
2000; 13: 106–108.
